DK0979093T3 - Terapeutisk virusmiddel, hvis udvikling kan standses - Google Patents

Terapeutisk virusmiddel, hvis udvikling kan standses

Info

Publication number
DK0979093T3
DK0979093T3 DK98907023T DK98907023T DK0979093T3 DK 0979093 T3 DK0979093 T3 DK 0979093T3 DK 98907023 T DK98907023 T DK 98907023T DK 98907023 T DK98907023 T DK 98907023T DK 0979093 T3 DK0979093 T3 DK 0979093T3
Authority
DK
Denmark
Prior art keywords
stopped
agent whose
virus agent
whose development
therapeutic virus
Prior art date
Application number
DK98907023T
Other languages
Danish (da)
English (en)
Inventor
Alexander Fred Markham
David Mark Meredith
Original Assignee
Univ Leeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leeds filed Critical Univ Leeds
Application granted granted Critical
Publication of DK0979093T3 publication Critical patent/DK0979093T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98907023T 1997-02-27 1998-02-24 Terapeutisk virusmiddel, hvis udvikling kan standses DK0979093T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9704046.3A GB9704046D0 (en) 1997-02-27 1997-02-27 Arrestable therapeutic
PCT/GB1998/000559 WO1998037905A1 (fr) 1997-02-27 1998-02-24 Agent viral therapeutique stoppant le developpement de tumeurs

Publications (1)

Publication Number Publication Date
DK0979093T3 true DK0979093T3 (da) 2002-04-02

Family

ID=10808384

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98907023T DK0979093T3 (da) 1997-02-27 1998-02-24 Terapeutisk virusmiddel, hvis udvikling kan standses

Country Status (11)

Country Link
EP (1) EP0979093B1 (fr)
JP (1) JP2001513634A (fr)
AT (1) ATE210990T1 (fr)
AU (1) AU6301398A (fr)
CA (1) CA2280690A1 (fr)
DE (1) DE69803052T2 (fr)
DK (1) DK0979093T3 (fr)
ES (1) ES2170479T3 (fr)
GB (1) GB9704046D0 (fr)
PT (1) PT979093E (fr)
WO (1) WO1998037905A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053505A2 (fr) 2000-01-21 2001-07-26 Biovex Limited Souches de virus herpetique
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0668355B1 (fr) * 1993-12-20 1999-04-07 Akzo Nobel N.V. Vaccin pour protéger des chevaux contre des infections du virus de l'herpes équin
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
IL118942A (en) * 1995-07-27 2002-09-12 American Cyanamid Co Nonviolent viruses used as killers - tumors and vaccines
GB9626029D0 (en) * 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors

Also Published As

Publication number Publication date
JP2001513634A (ja) 2001-09-04
WO1998037905A1 (fr) 1998-09-03
EP0979093A1 (fr) 2000-02-16
DE69803052T2 (de) 2002-07-25
CA2280690A1 (fr) 1998-09-03
AU6301398A (en) 1998-09-18
GB9704046D0 (en) 1997-04-16
EP0979093B1 (fr) 2001-12-19
PT979093E (pt) 2002-06-28
DE69803052D1 (de) 2002-01-31
ES2170479T3 (es) 2002-08-01
ATE210990T1 (de) 2002-01-15

Similar Documents

Publication Publication Date Title
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
IS6194A (is) Serínprótínasar úr fiski og notkun þeirra í lyf og snyrtivörur
DE60005953D1 (de) Stapelbare statische mischelemente
ES2135062T3 (es) Pirazolo y pirrolopiridinas.
ATE371372T1 (de) Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren
NO994014L (no) Arylsulfonamider og analoger derav og deres anvendelse for behandling av neurodegenerative sykdommer
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
ATE232396T1 (de) Oxydiertes thymosin beta 4
ATE247709T1 (de) 3'utr des menschliches prohibitin-gens
TR200100637T2 (tr) Yeni doğal ürün türevleri
BR0014372A (pt) Derivados de 5-hidroxissapogenina com atividade antidemência
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
DK0979093T3 (da) Terapeutisk virusmiddel, hvis udvikling kan standses
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
ATE258801T1 (de) Matrixprotein zusammensetzungen um apoptose zu induzieren
WO2003080800A3 (fr) Prevention et traitement de maladies au moyen d'angiogenese et/ou d'antigenes tumoraux
DE60019104D1 (de) Gentherapy von lungenkrankheiten
ATE360062T1 (de) Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren
ES2181160T3 (es) Derivados de 1,4-dihidropiridina y su utilizacion en terapia.
PT1150981E (pt) Composto nucleosidico terapeutico
ATE271878T1 (de) Verwendung von protein h als zytostattischer wirkstoff
TR200000916T2 (tr) İkameli piperidin türevleri.
UA36485A (uk) Спосіб лікування генералізованого пародонтиту